Hydrocortisone
DrugHydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
NCT Number: NCT02114710
The purpose of this study is to find out whether stress doses of hydrocortisone attenuate coagulation dysfunction in patients with septic shock. And discuss the probable mechanism by which little doses of hydrocortisone influence coagulation system in sepsis.
Looking for future studies?
Notify Me18 year–78 year
All sexes
Interventional
Phase 3
Patients were randomized to receive either low-dose hydrocortisone or matching placebo.Severity of coagulopathy was estimated using ISTH DIC score. We determined the complications and mortality in two groups, and analyzed the relationship between hydrocortisone and coagulopathy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
Time frame: 30 days after inclusion
Time frame: 30 days after inclusion
Time frame: 30 days after inclusion
MODS SOFA score
Looking for future studies?
Notify MeNanjing PLA General Hospital
Other
Study of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04401436
COVID-19, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06372483
Cardiovascular Diseases, Coagulation Disorder
Groningen, Netherlands
View Trial DetailsNCT05449834
Cardiovascular Diseases, Coagulopathy
Newcastle, New South Wales, Australia
View Trial DetailsNCT06635564
Bleeding Disorder, Brain Diseases
Vienna, Austria
View Trial Details